NEW YORK, Sept. 4, 2023 /PRNewswire/ — The binge-eating disorder treatment market size is expected to increase by USD 578.04 million from 2022 to 2027, registering a CAGR of 7.26%, according to the latest research report from Technavio. The increasing prevalence of binge-eating disorder is notably driving the market growth. The prevalence of binge-eating disorders across various age groups, races, and income levels serves as a significant driver for the growth of the binge-eating disorder treatment market. In the US, for example, this condition has a lifetime frequency of 2.6%. Notably, around 49% of individuals with binge-eating disorders have a history of two or more comorbid disorders, and approximately 79% of them experience at least one psychiatric disorder. The availability of medications to address impairments in patients’ lifestyles contributes to the revenue growth of the global binge-eating disorder treatment market. Moreover, antidepressants used for symptomatic treatment play a crucial role in preventing complications associated with binge-eating disorder, further propelling market expansion during the forecast period. View Sample Report!
Technavio has announced its latest market research report titled Global Binge-eating Disorder Treatment Market 2023-2027
Company Landscape
The binge-eating disorder treatment market is concentrated and the vendors are deploying organic and inorganic growth strategies to compete in the market.
Company Offerings
Alvogen Iceland ehf – The company offers binge-eating disorder treatment called Forfivo XL tablets under its subsidiary called Almatica.
Bausch Health Co. Inc. – The company offers a binge-eating disorder treatment called Aplenzin.
Chronos Therapeutics Ltd. – The company offers binge-eating disorder treatment drugs such as CTDP-002.
For the market’s vendor landscape highlights with a comprehensive list of vendors and their offerings – View Sample in a minutes
Key Market Segmentation
The binge-eating disorder treatment market report extensively covers market segmentation by distribution channel (offline and online), type (antidepressants, anticonvulsants, and stimulants and others), and geography (North America, Europe, Asia, and Rest of World (ROW)).
The market share growth by the offline segment will be significant during the forecast period. In 2022, the offline sector emerged as the dominant force in the global binge-eating disorder treatment market, commanding the largest share. The preference for offline distribution channels is driven by customers seeking product authenticity, verification, and assurance. To enhance their market presence regionally and globally, market players are making significant investments in organized retail stores within physical locations. This strategy aims to capitalize on the higher footfall experienced by offline stores, prompting vendors to establish brick-and-mortar outlets for the sale of binge-eating disorder treatment drugs. As the retail sector expands, facilitating improved product accessibility, it is expected that the offline segment’s growth will accelerate, consequently driving the overall expansion of the global binge-eating disorder treatment market throughout the forecast period.
Story continues
View Sample Report in minutes of this report for more highlights into the market segments.
Regional Market Outlook
North America is estimated to account for 38% of the global market during the forecast period. The growth of the regional market can be attributed to several key factors, including the high prevalence of binge-eating disorders and the availability of multiple treatment options. In North America, particularly in the US, there is a notable increase in the prevalence of binge-eating disorders, which creates favorable conditions for market expansion. Notably, The World Bank Group reported a significant rise in healthcare expenditure in the US in 2020, reaching USD 4.1 trillion or USD 12,530 per person, marking a 9.7% increase. Additionally, healthcare spending accounted for 19.7% of the country’s gross domestic product (GDP) in the same year. These indicators underscore the substantial investment and focus on healthcare in the US, further fueling the growth of the regional market during the forecast period.
For more key highlights on the regional market share of most of the above-mentioned countries.- View Sample Report
Companies Mentioned
Alvogen Iceland ehf
Bausch Health Co. Inc.
Chronos Therapeutics Ltd.
Currax Pharmaceuticals LLC
Eli Lilly and Co.
Johnson and Johnson Services Inc.
Lupin Ltd.
Omeros Corp.
Pyramid Healthcare Inc.
Rosewood Centers for Eating disorders
Sumitomo Pharma Co. Ltd.
Takeda Pharmaceutical Co. Ltd.
Timberline Knolls Residential Treatment Center
Tonix Pharmaceuticals Holding Corp.
Tryp Therapeutics Inc.
Viatris Inc.
VIVUS LLC
Walden Behavioral Care
Buy the report!
Market Dynamics
Significant Binge-eating Disorder Treatment Market Trends
The development and approval of new drugs is an emerging market trend. In response to the increasing prevalence of binge-eating disorders, pharmaceutical manufacturers are actively working on the development of new treatments for approval. For example, Tonix Pharmaceuticals Holding Corp. and Massachusetts General Hospital collaborated in 2022 to evaluate the potential of TNX-1900 as a treatment for patients with binge-eating disorders. Additionally, Tryp Therapeutics announced in January 2023 the interim results of its Phase II trial involving psilocybin (TRP-8803) for binge-eating disorder treatment, revealing an impressive average reduction of 80% in daily binge-eating episodes. This ongoing development and approval of novel drugs continue to be a driving force behind the growth of the binge-eating disorder treatment market during the forecast period.
Gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform
Related Reports:
The autism spectrum disorder therapeutics market is estimated to grow at a CAGR of 7.2% between 2022 and 2027. The market size is forecast to increase by USD 772.65 million. This report extensively covers market segmentation by distribution channel (retail pharmacy, hospital pharmacy, and online pharmacy), type (stimulants, selective serotonin reuptake inhibitors, antipsychotic drugs, sleep medications, and others), and geography (North America, Europe, Asia, and Rest of World). The increasing prevalence of ASD is notably driving the market growth.
The obsessive-compulsive disorder drugs market share is expected to increase by USD 266.78 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 5.55%. This report extensively covers obsessive-compulsive disorder drugs market segmentation by product (SSRI, TSA, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). One of the key factors driving growth in the obsessive-compulsive disorder drugs market is the rising prevalence of OCD.
Binge-eating Disorder Treatment Market Scope
Report Coverage
Details
Base year
2022
Historic period
2017-2021
Forecast period
2023-2027
Growth momentum & CAGR
Accelerate at a CAGR of 7.26%
Market growth 2023-2027
USD 578.04 million
Market structure
Concentrated
YoY growth 2022-2023(%)
6.24
Regional analysis
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 38%
Key countries
US, UK, Germany, China, and India
Competitive landscape
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled
Alvogen Iceland ehf, Bausch Health Co. Inc., Chronos Therapeutics Ltd., Currax Pharmaceuticals LLC, Eli Lilly and Co., Johnson and Johnson Services Inc., Lupin Ltd., Omeros Corp., Pyramid Healthcare Inc., Rosewood Centers for Eating disorders, Sumitomo Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Timberline Knolls Residential Treatment Center, Tonix Pharmaceuticals Holding Corp., Tryp Therapeutics Inc., Viatris Inc., VIVUS LLC, and Walden Behavioral Care
Market dynamics
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period.
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized
Table of contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
About US
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com
Global Binge-eating Disorder Treatment Market 2023-2027
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/binge-eating-disorder-treatment-market-size-is-set-to-grow-by-usd-578-04-million-from-2022-to-2027–the-increasing-prevalence-of-binge-eating-disorder-drives-the-market—technavio-301916031.html
SOURCE Technavio
